Dexcom receives FDA warning letter for two U.S. manufacturing facilities

(Reuters) -Medical device maker Dexcom (NASDAQ:DXCM) said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its shares down nearly 7% after the bell.

The warning letter identified issues in manufacturing processes and quality management system at Dexcom’s facilities in San Diego, California and Mesa, Arizona.

The company did not provide details about how many observations were made at the two sites, but said it does not "expect a material impact" from the letter to its manufacturing capacity or its sales guidance for fiscal year 2025.

Dexcom said it had already submitted responses to the so-called "Form 483" and is in the process of preparing a written response.

A Form 483 is a type of agency report containing "observations" that FDA inspectors "deem to be objectionable."

Dexcom manufactures its products at its headquarters in San Diego, California and at its manufacturing facilities in Mesa, Arizona and Penang, Malaysia, according to a recent regulatory filing.

It collectively operates about 80,600 square feet of laboratory space and about 159,600 square feet of controlled environment rooms across the three facilities.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.DXCM: is this perennial leader facing new challenges?

With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is DXCM one of them?

Unlock ProPicks AI to find out